Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?

Neurol Neuroimmunol Neuroinflamm. 2020 Jun 11;7(5):e811. doi: 10.1212/NXI.0000000000000811. Print 2020 Sep.

Authors

Cole Maguire¹, Teresa Frohman¹, Scott S Zamvil¹, Elliot Frohman¹, Esther Melamed²

Affiliations

¹ From the Department of Neurology (C.M., T.F., E.F., E.M.), Dell Medical School, Austin, TX; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco, CA.
² From the Department of Neurology (C.M., T.F., E.F., E.M.), Dell Medical School, Austin, TX; and Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco, CA. [email protected].

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents / therapeutic use*
COVID-19
Coronavirus Infections*
Drug Repositioning
Humans
Interferons / therapeutic use*
Multiple Sclerosis / drug therapy*
Pandemics*
Pneumonia, Viral*

Substances

Antiviral Agents
Interferons

Grants and funding

K08 AA027837/AA/NIAAA NIH HHS/United States